- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03154840
Relative Bioavailability Among Different Eutropin Formulations
July 18, 2017 updated by: LG Chem
A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers
- Compares and evaluates the relative bioavailability of single-dose subcutaneous administration of each of the Eutropin formulations to healthy male volunteers.
- Ensure safety and tolerability of single, subcutaneous administration of Eutropin formulations to healthy male volunteers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- A healthy male who is at least 19 years old but under 40 years of age at screening visit
- Those who weigh more than 50 kg at screening visit and whose body mass index (BMI) is greater than 19 kg / m2 but less than 28 kg / m2
- The result of the vital signs in the screening period.
- A person who is judged to be clinically insignificant in terms of physical or mental condition when the examinee medically judges the screening period physical examination
- Those who are not clinically significant when the examiner has medically judged the results of examination other than the items described in 17) and 18) of the exclusion criterion in the diagnosis laboratory test results in the screening period
- A person who consents to use a combination of effective contraceptive methods or medically appropriate contraceptive methods from the first administration of the clinical trial drug to the fourth administration (28 days) after the last administration of the drug for clinical trial and not to provide sperm
- Those who voluntarily decide to participate in clinical trials and observe the test subjects' precautions and agree in writing
Exclusion Criteria:
- Those who with a history or history of diabetes
- Those who with a history or history of malignancy
- Those who with a history or history of musculoskeletal disorders (including epiphyseal closure, scoliosis, etc.)
- Those who with history or history of endocrine system (including hypothyroidism, panhypopituitarism, etc.)
- Those who have a history of skin disease, including psoriasis and contact dermatitis, or who can not exclude the possibility of skin disease under the judgment of the examiner on physical examination conducted at the screening visit.
- Exclusion Criteria In addition to items 1) to 5), there are other clinically significant history or history of liver, kidney, digestive system, respiratory system, neuropsychiatry, blood /
- Persons with a history of somatropin and octreotide acetate or hypersensitivity reactions to cresol, glycerol or other drugs (non-steroidal anti-inflammatory drugs, antibiotics, etc.)
- Those who have participated in other clinical trials or bioequivalence tests within 90 days of the screening visit date
- Within 60 days before screening visit Those who have received blood (blood, whole blood, etc.) or blood transfusions
- Those who ingest herbal medicines or health functional foods within 14 days before the screening visit or those who are expected to affect the clinical trial within 7 days
- Within 14 days prior to screening visit, special medicines that may affect the clinical trial, or those who use general medicines within 7 days
- Screening Within 30 days prior to the visiting date Alcohol Abuse (alcohol-containing beverage> 21 units / week)
- Over 30 days before screening visit Overcame smoker (cigarette> 10 cigarettes / day)
- Within 7 days of screening visit Caffeine-containing foods Excessive intake (caffeinated foods> 3 times / week)
- Screening Within 7 days prior to the visit Date of intake of food containing xanthine
- As a result of urine nicotine test or urine drug screening test during the screening period
- Screening period serum test (hepatitis B test, human immunodeficiency virus (HIV) test, hepatitis C test, syphilis test) Result positive
Diagnosis of Screening Period In the case of a laboratory test, one or more of the following findings
- Fasting glucose> 110 mg / dL
- TSH Reference Range Above upper limit or below lower limit
- IGF-1 and IGFBP-3 according to the age of the test subjects. Reference range Above upper limit or below lower limit
- Vitamin B12 Reference range above or below the upper limit
- Insulin reference range above or below the upper limit
- More than twice the AST or ALT or Alkaline Phosphatase (ALP) reference range upper limit
- More than 1.5 times the upper limit of the bilirubin total reference range
- A 12-electrode electrocardiogram in the screening period revealed a QTc> 450 ms or clinically significant abnormalities
- Those who are judged to be inadequate to perform the clinical trial when the examiners judge them for other reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eutropin 4IU
|
Investigate the Relative Bioavailability among Different Eutropin Formulations
|
Experimental: Eutropin AQ 12IU
|
Investigate the Relative Bioavailability among Different Eutropin Formulations
|
Experimental: Eutropin Pen 36IU
|
Investigate the Relative Bioavailability among Different Eutropin Formulations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUClast of somatropin
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacokinetic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (Cmax) of somatropin
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacokinetic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
Area under the plasma concentration versus time curve (AUCinf) of somatropin
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacokinetic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
Time at which the Cmax is observed (Tmax) of somatropin
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacokinetic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
Elimination half-life time (t1/2β) of somatropin
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacokinetic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
IGF-1
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacodynamic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
IGF-BP3
Time Frame: Total three period at weekly intervals (Week 1, Week2, Week3)
|
Pharmacodynamic assessment
|
Total three period at weekly intervals (Week 1, Week2, Week3)
|
Monitoring of adverse reactions
Time Frame: Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Clinical significance is assessed by reviewing the general findings of individual subjects individually, and when there is a specific or tendency, analysis is conducted
|
Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Physical examination
Time Frame: Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Weight, Height
|
Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Vital Signs
Time Frame: Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Left-sided blood pressure (systolic / diastolic), pulse rate, tympanic temperature
|
Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Electrocardiogram
Time Frame: Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Ventricular rate, PR interval, QRS, QT/QTc
|
Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Laboratory test
Time Frame: Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
General blood test, general chemical test, clinical chemistry urinalysis, pancreas test
|
Week -4(Screening), Week 1, Week 2, Week 3, Week 5
|
Injection site reaction and Pain scale evaluation
Time Frame: Week 1, Week 2, Week 3
|
Ask the NRS about the degree of pain and evaluate it as 0-10
|
Week 1, Week 2, Week 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kyun-Seop Bae, AIDS Malignancy Consortium
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2017
Primary Completion (Actual)
July 10, 2017
Study Completion (Anticipated)
November 30, 2017
Study Registration Dates
First Submitted
April 25, 2017
First Submitted That Met QC Criteria
May 14, 2017
First Posted (Actual)
May 16, 2017
Study Record Updates
Last Update Posted (Actual)
July 21, 2017
Last Update Submitted That Met QC Criteria
July 18, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- LG-HGCL009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relative Bioavailability
-
TrippBio, Inc.Not yet recruitingRelative Bioavailability
-
Blade TherapeuticsCompletedRelative BioavailabilityAustralia
-
Hutchison Medipharma LimitedCompleted
-
AbbVieCompletedRelative BioavailabilityUnited Kingdom
-
TrippBio, Inc.Not yet recruiting
-
AstraZenecaCompletedPharmacokinetics | Relative Bioavailability | AUC | CmaxUnited States
-
Hartford HospitalSpero TherapeuticsCompleted
-
Forendo Pharma LtdRichmond Pharmacology LimitedCompletedRelative BioavailabilityUnited Kingdom
-
AstraZenecaCompletedRelative BioavailabilityUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100Germany